Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of …
Davis Polk Advises iKang Healthcare on Its Acquisition by Yunfeng Capital and Alibaba
Davis Polk is advising iKang Healthcare Group, Inc. in connection with its acquisition for $41.20 per common share or $20.60…
Accelerate Diagnostics, Inc. $150 Million Convertible Senior Notes Offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Accelerate…
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $1.5 Billion Refinancing
Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction…
Xencor, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $226.3 million public offering of common stock of…
Corvus Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $69 million SEC-registered common stock offering by…
Davis Polk Advises Agilent Technologies on Its Acquisition of Advanced Analytical Technologies
Davis Polk is advising Agilent Technologies, Inc. on its acquisition of privately held Advanced Analytical Technologies, Inc…
Atara Biotherapeutics, Inc. Follow-On Offerings
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with two…
Anthem, Inc. $2.1 Billion Senior Notes Offering and Remarketing of Subordinated Notes
Davis Polk advised the representatives of the several underwriters in an SEC-registered offering of $2.1 billion in…
Aimmune Therapeutics Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $176 million SEC-registered offering of 5,500,000…